Based on these data, the FDA approved tesamorelin (marketed as EGRIFTA) for the reduction of excess abdominal fat in HIVassociated lipodystrophy, not as a general weightloss drug for the wider population. Tesamorelin Risks and Considerations Like all hormonemodulating therapies, tesamorelin carries potential risks, including fluid retention, joint pain, injectionsite reactions, and effects on glucose metabolism in susceptible patients
If you are trying to access this site from the United States, please try heading to our homepage or our drug directory
Food and Drug Administration (FDA) for any purpose
Personalize Your Formula Your Options, Clearly Explained Choosing a medication doesn't have to be complex
Proper storage is crucial for maintaining the integrity and potency of 5 amino 1mq capsules in lab
The authors reported that AOD-9604 stimulated lipolysis in isolated adipocytes and that chronic daily treatment in obese Zucker rats produced reductions in body weight gain of more than 50% relative to untreated controls over the treatment period, without effects on insulin sensitivity or IGF-1 levels [3]